NovaBridge Biosciences (NBP) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of NovaBridge Biosciences $0.23, price $1.36, upside -83.0%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch NovaBridge Biosciences for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.6200 – $84.43 · fair‑value band $0.1500 – $0.2900 · the $1.36 price screens above the $0.2300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow NovaBridge Biosciences in your weekly email
Every Wednesday you see whether NovaBridge Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Show more
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Stock analysis
NovaBridge Biosciences (NBP) currently trades at $1.36, while our model-based Fair Value estimate is $0.2300, 83.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.1500 (bear) to $0.2900 (bull), the price of $1.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
NovaBridge Biosciences reported revenue of $0 in FY2025 versus $88.0M in FY2021. Reported net income was −$6.6M in FY2025.
Key figures
Market cap $173M · EPS (TTM) $−0.4900 · Return on equity −40.9% · Return on assets (EBIT) −88.7% · Free cash flow −$20.6M · Net cash $29.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 79% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −83%, NBP screens richer than that median.
Fair Value models
Bear $0.1500Fair Value $0.2300Bull $0.2900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−85.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.2%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.2%
’17
’18
’19
’20
’21
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−847.4% (2018) → −11,395.1% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−82.8% · Bottom 25%
Profitability
Return on assets−24.9% · Below median
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NovaBridge Biosciences Fair Value". https://www.fairvalue-calculator.com/stock/NBP
Frequently asked questions
Is NovaBridge Biosciences (NBP) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2300 versus a price of $1.36, about −83% upside (overvalued).
What is the fair value of NBP?
Our model-based fair value for NovaBridge Biosciences is $0.2300 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.36.
What is the quality score of NBP?
NovaBridge Biosciences has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NovaBridge Biosciences (NBP)?
Our model-based price target is the fair value of $0.2300 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1500, optimistic scenario $0.2900. It is a calculation from audited fundamentals, not an analyst target.
What is the NovaBridge Biosciences stock forecast for 2026?
Our models put fair value at $0.2300, about −83% upside versus a price of $1.36 (overvalued). Cautious scenario $0.1500, optimistic scenario $0.2900. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NovaBridge Biosciences (NBP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NovaBridge Biosciences it is $0.2300 per share (as of Sep 24, 2026), against a price of $1.36. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is NovaBridge Biosciences stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NBP trades above its calculated fair value: price $1.36, fair value $0.2300, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NBP?
No. The price is what the market pays today ($1.36); the fair value is what the company's own numbers justify ($0.2300). For NovaBridge Biosciences the two are $1.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is NovaBridge Biosciences worth?
The market values NovaBridge Biosciences at about $173M (market capitalisation, as of Sep 24, 2026). Per share that is $1.36; our models calculate a fair value of $0.2300 per share.
What do the bullish and bearish scenarios say about NBP?
Our models span a range for NovaBridge Biosciences: cautious scenario $0.1500, base $0.2300, optimistic $0.2900 per share (as of Sep 24, 2026, price $1.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NovaBridge Biosciences (NBP)?
Balance-sheet figures for NovaBridge Biosciences (as of Sep 24, 2026): return on equity −40.9%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is NBP from its 52-week high?
NovaBridge Biosciences trades at $1.36, about 79% below its 52-week high of $6.56 and 1% above the low of $1.34 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2300 is for.
Which stocks are comparable to NovaBridge Biosciences?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NovaBridge Biosciences stock attractive at the current price?
The data as of Sep 24, 2026: price $1.36, calculated fair value $0.2300 (−83%), Quality Score 66/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NBP calculated?
We run NovaBridge Biosciences through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. NovaBridge Biosciences itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NovaBridge Biosciences (NBP)?
The closing price on Oct 2, 2026 was $1.36. Our model-based fair value is $0.2300, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NovaBridge Biosciences right now?
The price sits above even our optimistic bull case ($0.2900). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.1500 to $0.2900) leaves room in how you read the outcome.
Key figures of NovaBridge Biosciences
How large is the market capitalisation of NovaBridge Biosciences (NBP)?
The market capitalisation of NovaBridge Biosciences is $173M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NovaBridge Biosciences (NBP)?
Earnings per share at NovaBridge Biosciences are $−0.4900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of NovaBridge Biosciences (NBP)?
The return on equity (ROE) of NovaBridge Biosciences is −40.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NovaBridge Biosciences (NBP)?
On an EBIT basis the return on assets of NovaBridge Biosciences is −88.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does NovaBridge Biosciences (NBP) generate?
The free cash flow of NovaBridge Biosciences is −$20.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does NovaBridge Biosciences (NBP) hold?
NovaBridge Biosciences holds more cash than debt, $29.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch NovaBridge Biosciences in the live analysis
One click puts NovaBridge Biosciences on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026